key: cord-0861661-k8irpw3m
authors: Goubran, Hadi; Seghatchian, Jerard; Sabry, Waleed; Ragab, Gaafar; Burnouf, Thierry
title: Platelet and extracellular vesicles in COVID-19 infection and its vaccines
date: 2022-05-21
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2022.103459
sha: 585e46bc1d69e45b7acd64f4b4bd686af2f3b9e1
doc_id: 861661
cord_uid: k8irpw3m

Platelets are at the crossroads between thrombosis and inflammation. When activated, platelets can shed bioactive extracellular vesicles [pEVs] that share the hemostatic potential of their parent cells and act as bioactive shuttles of their granular contents. In a viral infection, platelets are activated, and pEVs are generated with occasional virion integration. Both platelets and pEVs are engaged in a bidirectional interaction with neutrophils and other cells of the immune system and the hemostatic pathways. Severe COVID-19 infection is characterized by a stormy thromboinflammatory response with platelets and their EVs at the centre stage of this reaction. This review sheds light on the interactions of platelets, pEVS and SARS-CoV-2 infection and prognostic and potential therapeutic role of pEVs. The review also describes the role of pEVs in the rare adenovirus-based COVID-19 vaccine-induced thrombosis thrombocytopenia.

major histocompatibility complex (MHC) molecules capable of activating T cells. These functions are amplified by the vast amounts of pEVs generated when platelets are activated and pEVs have the same hemostatic and immunomodulatory potential [7] . Platelets and pEVs are, therefore, at the crossroad between hemostasis, inflammation, the complement and the immune systems with their various limbs.

On the one hand, their role is vital in the defense processes but can potentially degenerate into lifethreatening pathological processes on the other [8] .

The coagulant response is amplified at the platelet surface as platelets become activated. Similarly, pEVs have negatively charged pro-coagulant surface and PS that can support the binding of coagulation factors contributing to their increased 50~100-times prothrombinase and tenase complexes generation capacity compared to resting platelets [3, 9] Through their interactions with membrane surface markers like CD61+ (GPIIIa), pEVs may even reinforce the polymerization and strengthening of the fibrin clot [10] .

Furthermore, via their P-selectin (CD62P) receptor, they can interact with the P-selectin glycoprotein ligand-1 (PSGL-1) present on leukocytes [11] . Their interaction is not limited to the one leukocyte subset as pEVs activate and aggregate monocytes and stimulate the release of EVs expressing tissue factor (TF) from these cells [12] . pEVs are a reservoir of biological response modifiers (anti-leukocyte antibodies and lipids) in particular soluble (s) CD40L that can interact with CD40 and prime polymorphenuclear leucocytes inducing endothelial damage. They also express (sCD154), a pro-inflammatory mediator [13] . pEVs can be detected by various methods, including physical techniques; flow cytometry, microscopy, dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and tunable resistive pulse sensing (TRPS) or immunological and procoagulant-based assays or even cellular-based functional and internalization assays [3] . In a biological system, cells convey information to one another via hormones or cytokines. One instrument employed to transmit biological information and constituents to specific (target) cells is EVs.

The EVs cargo could be DNA, mRNA, microRNA, receptors, metabolites, cytoplasmic proteins, or pathological molecules. Therefore, EVs exert different functions upon endocytosis in recipient cells.

Recently, EVs have been unveiled to act as essential participants in various pathologies, including infection and atherogenesis [14] . Together with soluble P-selectin, pEVs correlate with the degree of platelet activation in peripheral arterial disease [15] and other inflammatory conditions. Therefore, pEVs may contribute to disease pathology and can be used as biomarkers reflecting platelet activation.

Platelets are positioned at the nexus of inflammation and host defense. Many bacteria are capable of interacting with platelets, inducing their aggregation. This interaction may be a direct interaction between a bacterial surface protein and platelet receptors like low-affinity type 2 receptor for the Fc portion of IgG, a receptor for immune complexes (FcγRIIA), GPIb, αIIbβ3, TLR2 and TLR4, or may be an indirect interaction enabled by proteins like fibrinogen and von Willebrand factor that binds to the bacterial surface and subsequently to a platelet receptor. Although some secreted bacterial products and toxins like polysaccharides are capable of platelet activation and can cause intravascular platelet aggregation with the generation of pEVs, a secondary co-signal is often needed for the process to occur.

Furthermore, platelet granules contain many proteins that modulate the immune response and microbicidal agents [16, 17] . They also prime macrophages and monocytes and are critical in recruiting and activating neutrophils, triggering intravascular thrombosis. In addition, migrating platelets can collect and bundle bacteria and exert direct antimicrobial effects [18] .

The mechanism through which viral infections induce platelet activation seems more complex as it involves the host microenvironment. The host inflammatory response mediators and the generated antigen-antibody complexes released in a pro-coagulant environment interact with megakaryocytes and J o u r n a l P r e -p r o o f activate platelets [18] , pEVs are shed with platelet/pEVs-induced immune modulation. These processes explain the noted initial inflammatory reactive thrombocytosis or thrombocytopenia in the context of viral infections, which results from either immune destruction or platelet activation, consumption and removal [19] . phagocytes. NETs also induce endothelial cell activation TF expression through Interleukin-1α and cathepsin G. NETs affect platelet function. Direct evidence demonstrates that the platelet-NET axis is by no means a one-way axis. Thrombin-stimulated platelets, with pEVs shedding, play a critical role in the activation/recruitment of neutrophils' NET release and reciprocally, NETs release recruits more platelet with further pEVs generation directly contributing to lung injury [21] .

Interestingly, the amount of generated microparticles, particularly pEVs, has served as disease severity marker and helped guide treatment in patients with certain viral infections like Dengue fever.

Not only do pEVs contribute to the pathology, but they also can serve as biomarkers of disease progression and severity [22, 23] .

Coronavirus Disease-19 (COVID- 19) , an acute respiratory illness in humans caused by coronavirus 2 (SARS-CoV-2), can produce severe symptoms and has caused millions of deaths, especially in older adults and those with underlying health conditions. This complex disease with multiorgan effect characterized by severe inflammation and thrombotic risks with multiorgan failure, became pandemic in 2020 [24, 25] .

Plasmacytoid dendritic cells drive an antiviral response with type I interferon molecule (IFN α and β) production in response to viral infections. They activate cytotoxic natural killer (NK) cells and CD8+ T cells to eliminate infected cells and are associated with secondary solid cytokine production [24] . inflammatory response and multiorgan failure with platelet-neutrophil aggregation, NETosis, activation and pEVs generation mediating its severe pathology. A bidirectional axis is generated, and the platelet aggregates formed due to the NET-platelet interaction bind to neutrophils via glycoprotein Ib (GPIb), further amplifying NETosis [27] . It is now documented that COVID-19 induces a hyperactive phenotype of platelets associated with a dramatic increase in platelet dense granule secretion [28] . The abnormal levels of platelet Factor-4 (PF4/CXCL4) and RANTES/CCL5 and other cytokines and chemokines also attest to platelet activation in severe COVID-19 patients [29, 30] . As expected, increased pEV formation has been associated with systemic inflammation in COVID-19 patients *31].

As previously mentioned, TF contributing to thrombogenesis is induced, in part, by NETosis but also in various cell types during viral infection. TF-positive EVs (TF+EVs) shedding from TF-expressing cells can be assayed using an extracellular vesicle tissue factor (EVTF) activity capture test. As previously demonstrated in animal models, in humans, TF and TF+EVs were observed in the peripheral blood mononuclear cells, platelet-monocyte aggregates, and neutrophils in severely affected COVID-19 patients [32] . EVTF activity and raised D-Dimer correlated with severity, thrombosis, and mortality in COVID-19 patients [32] . Early and intense platelet activation characterizes COVID-19 and contributes, therefore, to the thromboinflammatory manifestations of the disease.

Interestingly, platelets exposed in vitro to SARS-CoV-2 underwent activation. This observation was replicated using SARS-CoV-2 pseudo-viral particles or purified recombinant SARS-CoV-2 spike protein S1 subunits. Human platelets express CD147, a putative co-receptor for SARS-CoV-2. In the J o u r n a l P r e -p r o o f presence of anti-CD147 antibodies, spike-dependent platelet activation, aggregation, and granule release and expression of soluble P-selectin and pEVs are suppressed [33] .

When the number and surface characteristics of EVs were determined in the plasma of 41 adult PCR positive, COVID-19 patients and compared to the results of 37 sex-and age-matched healthy controls, the number of EVs was significantly higher in patients compared to controls (p < 0.001).

Patients exhibited substantially higher numbers of pEVs, and EVs derived from endothelial cells (eEVs), leukocytes, or neutrophils than controls. TF-expressing EVs and angiotensin-converting 2 enzymepositive EVs (ACE2+EVs) were observed equally in both groups [34] .

In another study, platelet activity was assessed by the expression and distribution of HMGB1 and von Willebrand factor and the accumulation of pEVs and HMGB1+ pEVs in the plasma. P-selectin upregulation was not detectable on the platelet surface in 55% of patients; conversely, the concentration of soluble P-selectin was increased in plasma. The plasma concentration of HMGB1+ pEVs at admission was an independent predictor of the clinical outcome [33] .

In a detailed longitudinal study, EVs originating from various cells were measured using flow cytometry and phospholipid-dependent clotting time (PPL) in hospitalized COVID-19 patients and trended in association with clinical outcomes within 48 hours of hospital admission at discharge and 30 days after that [34] . A broad spectrum of EVs was quantitated and included eEVs, pEVs, leukocytederived EVs and TF+EVs, ACE2+EVs, platelet-derived growth factor receptor-β (PDGF-β)+ and SARS-CoV-2-nucleoprotein (NP)+ were also assayed. From baseline to 30-days post-discharge, significantly decreased plasma concentrations of eEVs (E-Selectin+), endothelium-derived bearing TF (E-Selectin+ TF+), endothelium-derived bearing ACE2 (E-Selectin+ACE2+) and leukocyte-EVs bearing TF (CD45+TF+) were observed respectively. In contrast, pEVs (P-Selectin+) and leukocyte-derived EVs (CD45+), as well as PPL, increased from baseline to 30-days post-discharge. During the observation period, TF+EVs,

ACE2+EVs, PDGF-β+, and SARS-CoV-2-NP+ were unchanged. Interestingly, a cut-off of a P-Selectin + EVs >1,054/µL was associated with thrombotic events (p = 0.024) and an E-Selectin + EVs ≤531/µL with poor outcome and death (p 0.026). At 30-days P-Selectin+ and CD45 + EVs abnormalities were associated with persistence of the symptoms (p < 0.0001) [35] .

From all published and observed data, it is evident that aging and the presence of comorbidities confer a worse COVID-19 prognosis. Intimate crosstalk exists between malignancy and the platelets with the generation of pEVs [36, 37] . Malignancy, therefore, contributes to the generation of EVs as well as pEVs, and one would expect an amplified EVs response in the context of COVID-19 infection. Twentythree malignant patients with a positive PCR test were recruited and compared to 19 COVID-19 nonmalignant patients and 20 healthy volunteers concerning total EVs, pEVs, eEVs, CD62 activated platelets and CD41 platelet marker. Even though COVID-19 malignant patients had significantly lower platelets counts than COVID non-malignant ones, their total EVs and eEVs were considerably higher, with no significant difference in pEVs between both groups [38] . A considerable accumulation of total EVs, pEVs, eEVs, and activated platelets was observed in COVID-19 affected patients compared to healthy controls. This highlights the importance and need for prevention in the context of cancer and the value of using biomarkers capable of identifying severe cases.

Since thromboinflammation is the hallmark of severe COVID-19 infection, it often results in T cell exhaustion and lymphopenia. Lymphopenia and its severity levels may serve as reliable predictive factors for COVID-19 clinical outcomes, including mortality, need for intensive care, and oxygen requirements [39] . In a study on PS, a marker of dying cells, activated platelets and pEVs, during the clinical course of COVID-19 infection, Rausch et al. [40] found a high number of blood cells loaded with PS+ pEVs for weeks after the initial COVID-19 diagnosis. PS+ pEVs are preferentially bound to CD8+ T cells interfering with the programmed death-ligand expression rather than memory T cells. The level of J o u r n a l P r e -p r o o f these markers correlated strongly with increased disease severity [40] . Other studies have also highlighted the role of vascular cell adhesion molecule 1 and annexin A5 [41] .

Virion internalization, viral RNA sensing, and their consequent impact on platelet function have been studied recently [32, 42] . The increased incidence of micro thrombosis with hyperactive platelets sporadically containing viral RNA in COVID-19 infected patients attracted, therefore, the attention of [43] . Furthermore, platelets interacting in vitro with SARS-CoV-2, SARS-CoV-2 pseudo-viral particles or purified recombinant SARS-CoV-2 spike protein S1 subunits undergo activation [32] . Immunofluorescent imaging of platelets from patients with COVID-19 confirmed the presence of SARS-CoV-2 proteins, whereas there was no detection of viral RNA by real-time quantitative polymerase chain reaction. SARS-CoV-2 elicits unconventional CD147-dependent platelet activation in COVID-19, a process that could be abated in the presence of anti-CD147 antibodies [33] . Platelets, therefore, seem to internalize SARS-CoV-2 virions directly or through the attachment to microparticles. This leads to rapid digestion, programmed cell death, and pEVs release [43] .

Targeting neutrophils and the neutrophil inflammation-dependent cascade, platelet activation, and aggregates could restrain thromboinflammation and limit COVID-19 consequences. A broad palette of J o u r n a l P r e -p r o o f medications including steroids, anti-inflammatory agents, anti-platelet agents, anti-cytokines and anticoagulants are now offered to COVID-19 patients [25] .

As it is now clear that platelets and pEVs are at the crossroads of thrombosis and inflammation in COVID-19, inhibitors of platelet function seem to be appealing tools. A retrospective analysis has recently emphasized that among COVID-19-positive patients, pre-diagnosis low-dose aspirin prescription was associated with a 2-fold decrease in 14-day and 30-day overall mortality [44] . P2Y12 receptor inhibitors have been shown to display anti-inflammatory effects in many, and current studies evaluate their benefit in COVID-19.

As many as 40% of patients admitted to the hospital due to COVID-19 have acute kidney injury, with coagulation abnormalities, the leading cause of impaired function. Through inhibition of PS-mediated coagulopathy, early anticoagulation allows maintenance of unobstructed blood circulation [45] .

Therefore, many meta-analyses and guidelines supported the use of anticoagulation and thromboprophylaxis for hospitalized patients with COVID-19 infection [46, 47] .

The scientific community spared no effort to rapidly develop vaccines in the pandemic. Some of the novel approaches looked into the potential of EVs as potential targets or tools. Ongoing EVs-based strategies for treating COVID-19, including mesenchymal stem cell (MSC)-EVs, drug-EVs, vaccine-EVs, platelet-EVs, and others, have been contemplated and are currently being studied [48] .

Furthermore, interfering with SARS-CoV-2 entry into a host cell using soluble or EV-bound seems promising in vitro. Considering their crucial role in COVID-19 pathology, targeting the platelets and their pEVs appears to be a very reasonable approach [25] . In an attempt to eliminate the harmful cytokines and probably the EVs in patients with severe COVID-19 disease, plasma exchange was considered with some success in limited series. Inflammatory cytokine levels (TNF-α, IFN-γ, IL-1, IL-6, and IL-17), and acute-phase reaction proteins including ferritin and CRP had a significant decrease following plasma J o u r n a l P r e -p r o o f excahnge courses [49, 50] . However, the role of plasma exchange in eliminating pEVs is only hypothetical and has not been studied.

Numerous days after ChAdOx1 nCoV-19 or Ad26.COV2.S vaccination [52] . As in heparin-induced thrombocytopenia (HIT), PF4 antibodies are thought to activate platelets via binding to the FcγRIIA receptor leading to their aggregation and pEVs shedding [53] . Similar to HIT, and with the contribution of pEVs, the process is associated with an increased risk of thrombosis [54] . The culprit component of the vaccine has not been identified [55] . Nevzorova et al. confirmed that PF4-containing pathogenic immune complexes lead to platelet activation, PS and P-selectin exposure on the outer leaflet of the platelet plasma membrane J o u r n a l P r e -p r o o f together with the shedding of procoagulant pEVs expressing PS [56] . In addition, HIT Ab complexes induced TF expression by monocytes and the release of TF-EVs. Therefore, it is likely that the pathogenesis of VITT involves FcγRIIA receptor pathways, the same pathway implicated in SARS-CoV-2 induced thrombogenesis, with circulating PF4 antibodies complexes binding platelets with the release of procoagulant pEVs and direct activation of the endothelium by HIT antibody complexes with enhanced thrombogenicity [55] . The resultant enhanced PS and TF expression, platelet recruitment and pEVs amplification and subsequent thrombin generation are more likely to occur in the cerebral venous system [57] . Interestingly, mRNA-based vaccines do not seem to share these properties and do not seem to confer an increased risk of clot formation [58] .

COVID-19 caused by SARS-CoV-2 with its thromboinflammatory consequences and mortality has highlighted the need for a better understanding of the crucial role played by the platelets and their pEVs at the crossroads of thrombosis and inflammation. EVs and pEVs will probably be used shortly as prognostic markers that could affect the decision-making process and will likely be used as targets or vehicles to develop future therapeutic tools.

An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful?

Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers

Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine

Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and disease

Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses

Clearance of platelet microparticles in vivo

Platelets and platelet extracellular vesicles in hemostasis and sepsis

Platelets: "multiple choice" effectors in the immune response and their implication in COVID-19 thromboinflammatory process

Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets

Circulating microparticles alter formation, structure and properties of fibrin clots

Cell-derived microvesicles/microparticles in blood components: Consequences for transfusion recipients

Microparticles in stored red blood cells as potential mediators oftransfusion complications

Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury

Extracellular Vesicles: Versatile Nanomediators, Potential Biomarkers and Therapeutic Agents in Atherosclerosis and COVID-19-Related Thrombosis

Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers

Platelets and infection

Platelets mediate host defense against Staphylococcus aureus through direct bactericidal activity and by enhancing macrophage activities

Platelets as key players in inflammation and infection

Platelets and infection -an emerging role of platelets in viral infection. Front Immunol

Influenza virus H1N1 activates platelets through FcgammaRIIA signaling and thrombin generation

Platelet-Mediated NET Release Amplifies Coagulopathy and Drives Lung Pathology During Severe Influenza Infection. Front Immunol

Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection

Microparticles as prognostic biomarkers in dengue virus infection

Platelet extracellular vesicles in COVID-19: Potential markers and makers

Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy

NETosis: how vital is it?

Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response

provided an elegant demonstration that COVID-19 induces a hyperactive phenotype on platelets associated to a dramatic increase in platelet dense granule secretion

Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19

Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus

Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19

Extracellular Vesicles and Citrullinated Histone H3 in Coronavirus Disease

Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19

Platelet microparticles and cancer: An intimate cross-talk

Platelet-cancer interactions

Circulating microparticles and activated platelets as novel prognostic biomarkers in COVID-19; relation to cancer

Lymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases

Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients

Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserinedependent manner

Human Platelets and Influenza Virus: Internalization and Platelet Activation

SARS-CoV-2 Initiates Programmed Cell Death in Platelets

Association of mortality and aspirin prescription for COVID-19 patients at the veterans health administration

Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. Front Cell Dev Biol

Anticoagulation treatment for patients with coronavirus disease 2019 (COVID-19) and its clinical effectiveness in 2020: A meta-analysis study. Medicine (Baltimore)

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge. Front Mol Biosci

Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology

Improvement of clinical outcome, laboratory findings and inflammatory cytokines levels using plasmapheresis therapy in severe COVID-19 cases

HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Weisel JW Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis

No Apparent Association Between mRNA COVID-19 Vaccination and Venous Thromboembolism. Under review